
|Articles|January 19, 2006
FDA clears laser device for BPH
Trimedyne, Inc., Irvine, CA, has received FDA approval to market its VaporMAX Fiber for use with its Holmium lasers to treat BPH.
Advertisement
Trimedyne, Inc., Irvine, CA, has received FDA approval to market its VaporMAX Fiber for use with its Holmium lasers to treat BPH. The new side-firing laser fibers vaporize an average of 3 grams of soft tissue over 60 minutes of use. This faster vaporization rate minimizes physician and operating room time, according to the company.
The company also said that product testing has indicated that the fibers are more durable than other side-firing fibers, meaning that one device should be sufficient to treat even large prostates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











